ProCE Banner Activity

CME

Breakfast With the Experts: Updates in the Management of Patients With Metastatic Castration-Resistant Prostate Cancer

Multimedia
In this on-demand webcast of a live symposium, expert faculty highlight the latest safety and efficacy evidence supporting optimal management of patients with metastatic castration-resistant prostate cancer, including data on approved therapies in new settings and advances in both systemic and targeted therapies.

Physicians: Maximum of 1.50 AMA PRA Category 1 Credits

Released: March 15, 2022

Expiration: March 14, 2023

No longer available for credit.

Share

Faculty

Matthew R. Smith

Matthew R. Smith, MD, PhD

Professor of Medicine
Harvard Medical School
Director
Genitourinary Malignancies Program
Massachusetts General Hospital Cancer Center
Boston, Massachusetts

Rana R. McKay

Rana R. McKay, MD

Associate Professor of Medicine
Division of Hematology/Oncology
Department of Medicine
University of California, San Diego
Genitourinary Oncology Team Lead
Moores Cancer Center
La Jolla, California

Michael Schweizer

Michael Schweizer, MD

Associate Professor
Clinical Research Division
Department of Medical Oncology
University of Washington
Fred Hutchinson Cancer Research Center
Seattle, Washington

Provided by

Provided by Clinical Care Options, LLC
ProCE Banner

Supporters

Supported by educational grants from

Bayer Healthcare Pharma

Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC

Novartis Pharmaceuticals Corp Advanced Accelerator Applications

Sanofi Genzyme

Target Audience

This educational program is intended for medical oncologists, surgical oncologists, pathologists, and other healthcare professionals who treat patients with prostate cancer.

Learning Objectives

Upon completion of this activity, participants should be able to:
  • Integrate novel therapies into practice to optimize the care of patients with mCRPC, considering the available evidence and patient and disease characteristics
  • Evaluate novel therapeutically actionable molecular targets that hold promise as predictive or prognostic biomarkers for patients with mCRPC
  • Plan therapy for patients with mCRPC and bone metastases in the frontline and subsequent-line treatment settings
  • Navigate barriers to identify and enroll qualified patients with mCRPC in ongoing clinical trials actively investigating agents with novel mechanisms of action

Disclosure

Clinical Care Options, LLC (CCO) requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose all financial conflicts of interest (COI) they may have with ineligible companies. All relevant COI are thoroughly vetted and mitigated according to CCO policy. CCO is committed to providing its learners with high-quality CME/CE activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company.

The faculty reported the following relevant financial relationships or relationships to products or devices they have with ineligible companies related to the content of this educational activity:

Program Director Disclosure

Program Director

Matthew R. Smith, MD, PhD

Professor of Medicine
Harvard Medical School
Director
Genitourinary Malignancies Program
Massachusetts General Hospital Cancer Center
Boston, Massachusetts

Matthew R. Smith, MD, PhD, has disclosed that he has received consulting fees from Amgen, Astellas, Bayer, Janssen, Lilly, and Pfizer.

Faculty Disclosure

Primary Author

Rana R. McKay, MD

Associate Professor of Medicine
Division of Hematology/Oncology
Department of Medicine
University of California, San Diego
Genitourinary Oncology Team Lead
Moores Cancer Center
La Jolla, California

Rana R. McKay, MD, has disclosed that she has received consulting fees from AstraZeneca, Aveo, Bayer, Bristol-Myers Squibb, Calithera, Caris, Dendreon, Exelixis, Johnson & Johnson, Merck, Myovant, Novartis, Pfizer, Sanofi, Sorrento, and Tempus.

Michael Schweizer, MD

Associate Professor
Clinical Research Division
Department of Medical Oncology
University of Washington
Fred Hutchinson Cancer Research Center
Seattle, Washington

Michael Schweizer, MD, has disclosed that he has received consulting fees from AstraZeneca, PharmaIn, and Sanofi and funds for research support paid to his institution from Ambrx, AstraZeneca, Bristol-Myers Squibb, Hoffmann-La Roche, Immunomedics, Janssen, Madison Vaccines, Merck, Pfizer, SignalOne Bio, Tmunity, and Zenith Epigenetics.

Staff Disclosure

Staff

Marie N. Becker, PhD

Scientific Director

Marie N. Becker, PhD, has no relevant conflicts of interest to report.

Gordon Kelley,

Clinical Editor
Clinical Care Options, LLC

Gordon Kelley has no relevant conflicts of interest to report.

Krista Marcello,

Associate Managing Editor

Krista Marcello has no relevant conflicts of interest to report.

Kevin Obholz, PhD

Editorial Director, Hematology/Oncology

Kevin Obholz, PhD, has no relevant conflicts of interest to report.

Timothy A. Quill, PhD

Senior Managing Editor

Timothy A. Quill, PhD, has no relevant conflicts of interest to report.

Justine Stanley, MSc

Editorial Contributor

Justine Stanley has no relevant conflicts of interest to report.

Instructions for Credit

Accreditation

Joint Accreditation Statement

In support of improving patient care, Clinical Care Options, LLC (CCO) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Physician Continuing Medical Education

Credit Designation

CCO designates this enduring material for a maximum of 1.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Additional Information

Participation in this self-study activity should be completed in approximately 1.5 hours. To successfully complete this activity and receive credit, participants must follow these steps during the period from March 15, 2022, through March 14, 2023:

1. Register online at http://www.clinicaloptions.com.
2. Read the target audience, learning objectives, and faculty disclosures.
3. Study the educational activity online or printed out.
4. Submit answers to the posttest questions and evaluation questions online.

You must receive a test score of at least 65% and respond to all evaluation questions to receive a certificate. After submitting the evaluation, you may access your online certificate by selecting the certificate link on the posttest confirmation page. Records of all CME/CE activities completed can be found on the "CME/CE Manager" page. There are no costs/fees for this activity.

Program Medium

This program has been made available online.


Goal


The goal of this program is to improve the knowledge and competence of learners in effort to optimize treatment for patients with prostate cancer.